{"preliminary_commentary":{"by_channel":{"youtube":9,"x_thread":5,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00003653\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["buserelin"],["goserelin"],["leuprolide"]],"indication":"prostate cancer with rising PSA after radiotherapy","name":"PR-7","nct_id":"NCT00003653","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pr-7-nct00003653. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Intermittent Androgen Suppression","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Continuous Androgen Suppression","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)","SWOG Cancer Research Network"],"completion_date":{"date":"2013-01-10","type":"ACTUAL"},"conditions":["Prostate Cancer"],"enrollment":{"count":1386,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"bicalutamide","otherNames":[],"type":"DRUG"},{"name":"buserelin","otherNames":[],"type":"DRUG"},{"name":"cyproterone acetate","otherNames":[],"type":"DRUG"},{"name":"flutamide","otherNames":[],"type":"DRUG"},{"name":"goserelin","otherNames":[],"type":"DRUG"},{"name":"leuprolide acetate","otherNames":[],"type":"DRUG"},{"name":"nilutamide","otherNames":[],"type":"DRUG"}],"last_update":"2021-06-23","lead_sponsor":"NCIC Clinical Trials Group","official_title":"A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients With Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2010-10-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"2 years"}],"references":[{"citation":"Klotz L, Correia A, Zhang W. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(2):179-83. doi: 10.1038/sj.pcan.4500792.","pmid":"15809670","type":"BACKGROUND"},{"citation":"Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546.","pmid":"22931259","type":"RESULT"},{"citation":"Hamilton RJ, Ding K, Crook JM, O'Callaghan CJ, Higano CS, Dearnaley DP, Horwitz EM, Goldenberg SL, Gospodarowicz MK, Klotz L. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. Eur Urol. 2021 Apr;79(4):446-452. doi: 10.1016/j.eururo.2020.12.031. Epub 2020 Dec 31.","pmid":"33390282","type":"DERIVED"},{"citation":"Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M, Crook JM. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015 Apr 1;33(10):1151-6. doi: 10.1200/JCO.2014.58.2973. Epub 2015 Mar 2.","pmid":"25732157","type":"DERIVED"}],"start_date":{"date":"1999-01-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT00003653"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pr-7-nct00003653"}